Targeting IL-1 in Sjögren's syndrome
Akiko Yamada1, Rieko Arakaki, Yasusei Kudo
1Institute of Health Biosciences, Department of Oral Molecular Pathology, The University of Tokushima Graduate School, 3-18-15 Kuramoto, Tokushima, 770-8504, Japan.
Expert Opinion on Therapeutic Targets
|January 17, 2013
Summary
Interleukin-1 (IL-1) is crucial in autoimmunity, particularly Sjögren's syndrome (SS). Inhibiting IL-1's pathogenic functions may offer effective therapeutic strategies for treating SS.
Area of Science:
- Immunology
- Autoimmunity
- Ophthalmology
Background:
- Interleukin-1 (IL-1) is a key cytokine involved in diverse cellular functions and immune responses.
- Numerous studies highlight IL-1's significant roles within the immune system.
- This review specifically examines the connection between IL-1 and the pathogenesis of autoimmune diseases.
Purpose of the Study:
- To review the biological functions of the IL-1 family and their receptors (IL-1Rs).
- To elucidate the role of IL-1 in the pathogenesis of Sjögren's syndrome (SS), focusing on immune responses and target tissues.
- To explore potential therapeutic strategies involving IL-1 inhibition for SS.
Main Methods:
- Overview of IL-1 family and IL-1R biological functions and signaling pathways.
- Detailed examination of IL-1's involvement in Sjögren's syndrome pathogenesis, including immune responses and ocular manifestations.
- Review of therapeutic strategies targeting IL-1 inhibition in SS.
Main Results:
- IL-1 signaling through IL-1Rs is integral to maintaining homeostasis in various immune systems.
- IL-1 significantly contributes to the immune responses and target tissue pathology observed in Sjögren's syndrome.
- IL-1 plays a role in ocular mucosal lesions characteristic of SS.
Conclusions:
- IL-1 is critical for the initiation and progression of Sjögren's syndrome.
- IL-1 modulates systemic and local immune responses and supports epithelial cell survival and defense.
- Targeting IL-1's pathogenic functions presents a promising therapeutic avenue for SS treatment.
Related Concept Videos
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...